<DOC>
	<DOCNO>NCT00094848</DOCNO>
	<brief_summary>The purpose study evaluate safety , efficacy exposure TRM-1 subject relapse refractory Non-Hodgkin 's Lymphoma ( NHL ) .</brief_summary>
	<brief_title>Study TRM-1 ( TRAIL-R1 Monoclonal Antibody ) Subjects With Relapsed Refractory Non-Hodgkin 's Lymphoma ( NHL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Primary Relapsed refractory histologically confirm NonHodgkin 's Lymphoma Previously treat least 1 therapeutic regimen relapse progress fail achieve response last regimen 18 year age old Primary Received nonFDA approve investigational agent within last 4 week Received cancer therapy ( chemotherapy , biological therapy [ include hormonotherapy ] , radiation therapy immunosuppressant within last 3 week , 8 week monoclonal antibody , radioimmunotherapy nitrosourea Eligible hematopoietic stem cell transplant ( HSCT ) autologous HSCT within last 16 week Prior history allogeneic HSCT HIV , AIDSrelated lymphoma , central nervous system ( CNS ) lymphoma , HepatitisB HepatitisC Infection require antibiotic within last 4 week Major surgery within last 4 week Pregnant breastfeed woman History cancer within past 5 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>